Thiazolide Agents Against Coronavirus Replication

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for illnesses caused by coronaviruses, such as SARS-CoV-2, are inadequate in reducing symptom duration and hospitalization rates, and there is a need for effective prevention methods against viral respiratory illnesses.

Innovation Solution

Administering thiazolide agents like nitazoxanide or tizoxanide to produce effective plasma concentrations, which inhibit virus replication, transmission, and alleviate symptoms, thereby reducing illness duration and hospitalization rates, and preventing viral respiratory illnesses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for coronavirus are used, then patients receive standard care, but symptom duration and hospitalization rates remain high

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidsymptom duration

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent introduces a novel pharmacological parameter (thiazolide administration) to change the treatment paradigm. Clinical trials demonstrated that thiazolide treatment achieved an 80% reduction in symptom duration compared to placebo, transforming the temporal parameter of disease course without requiring changes to existing treatment protocols

Inventive Principle:

Principle #35Parameter changes

2Loss of time

If thiazolide agents are administered to treat coronavirus, then symptom duration is reduced, but new treatment protocols must be established

Engineering Contradiction:

Improvesymptom durationVSAvoidtreatment protocol complexity

Core Design Contradiction:

Loss of timeVSDevice complexity

Solution Approach 1:

Thiazolide agents demonstrate broad-spectrum antiviral activity against multiple coronavirus strains (SARS-CoV-2, SARS-CoV-1, MERS-CoV, and endemic coronaviruses), allowing a single treatment protocol to address diverse viral threats. This multi-functionality simplifies the overall treatment landscape despite the introduction of a new therapeutic agent

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Reliability

If prevention methods are implemented, then infection rates are reduced, but intervention measures must be taken

Engineering Contradiction:

Improveprevention effectivenessVSAvoidprevention implementation

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent enables preliminary pharmacological intervention to prevent coronavirus infection or progression to severe disease. By administering thiazolide agents before symptom onset or during early infection, the treatment prevents viral replication and progression, eliminating the need for complex containment measures while maintaining high prevention effectiveness

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20230330069A1Use of thiazolides against coronaviruses

Publication Date: 2023.10.19 ROMARK LAB L C

AI summary

Disclosed is use of thiazolides, such as nitazoxanide and/or tizoxanide, against viruses belonging to the Coronaviridae family, such as viruses belonging to the Orthocoronavirinae subfamily.